Henry Schein (HSIC) has drawn investor attention recently as its stock performance over the past month and past 3 months, along with solid value and profitability metrics, has put its current pricing in sharper focus.

At a share price of $87.82, Henry Schein has seen its 30 day share price return of 9.88% and year to date share price return of 14.32% feed into a 1 year total shareholder return of 27.15%, which suggests positive momentum has been building over both shorter and longer time frames.

If you want to see what else is moving in healthcare technology and services, this is a good moment to scan for other opportunities through our curated list of 39 healthcare AI stocks.

The recent climb in Henry Schein’s share price has bulls pointing to improving returns and a sizable implied intrinsic discount, while bears highlight how close it sits to analyst targets. Which side does the valuation actually support next?

Most Popular Narrative: 30% Undervalued

Henry Schein’s most followed narrative points to a fair value of $88.07 versus the current $87.82 share price. The gap is described as being driven largely by expectations for steadier earnings and margin improvement rather than aggressive growth.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments. This is described as supporting structurally higher gross margins and likely driving earnings expansion.

Curious what sits behind that margin story, the earnings path, and the future P/E that ties it all together? The full narrative lays out a detailed roadmap of revenue mix shifts, profit assumptions, and how those cash flows are discounted to arrive at today’s fair value anchor.

Result: Fair Value of $88.07 (UNDERVALUED)

However, Henry Schein’s story could look different if competitive pricing squeezes distribution margins, or if medical segment growth stays soft and weighs on overall profitability.

Next Steps

Seeing both optimism and caution around Henry Schein, want to test the story against the numbers yourself and move quickly from headline to conviction? Start by weighing the company’s mix of potential upsides and flagged issues through 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Henry Schein?

If you stop with Henry Schein, you might miss other opportunities that fit your style. Use the Simply Wall St Screener to round out your watchlist with targeted ideas.

• Spot potential turnarounds early by scanning 20 elite penny stocks with strong financials that already show stronger financial footing than many expect at this price range.
• Zero in on quality at a measured price by checking companies in the 48 high quality undervalued stocks that pair solid fundamentals with room for a rerating.
• Prioritise resilience by reviewing 81 resilient stocks with low risk scores that combine steadier balance sheets with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.